Journal
TRENDS IN PHARMACOLOGICAL SCIENCES
Volume 36, Issue 7, Pages 419-421Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tips.2015.04.012
Keywords
IVIg; multiple sclerosis; biomarkers; immunotherapy; autoimmunity; inflammation
Categories
Ask authors/readers for more resources
Despite promising clinical trials, intravenous immunoglobulin (IVIg) therapy in relapsing-remitting multiple sclerosis (MS) has met with uncertainties that might be attributed to small patient cohorts, heterogeneity in the patients, dose of IVIg, or the duration and window of treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
